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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

A FALSE SENSE OF SAFETY: HOW THE DRUG QUALITY AND
SECURITY ACT FAILS TO PROTECT PATIENTS FROM HARM

ABSTRACT
For many years, the art of pharmaceutical compounding in the United
States has been largely an overlooked and under regulated industry providing
millions of patients each year with customized medications. Only after
piecemeal enforcement resulted in hundreds of injuries and deaths in an event
known as the New England Compounding Center Tragedy, did legislators and
regulatory agencies refocus attention on current regulations in pharmaceutical
compounding. Congress passed the Drug Quality and Security Act providing
clarification for state and federal agencies as to their specific regulatory
authority and responsibility to ensure patient safety in pharmaceutical
compounding. However, the Drug Quality and Security Act instead created an
ineffective and inefficient voluntary registration system, missed opportunities
to ensure safer compounded pharmaceutical products, and did not provide
other mechanisms or additional resources to aid state agencies in regulation
and to increase patient-safety of compounded medications. This comment
hopes to elaborate and identify several of the problems legislators at the state
and federal level have seemingly overlooked and to suggest regulatory actions
that may be taken to improve overall safety of all compounded preparations
and the patients that receive them.
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I. INTRODUCTION
In 2013, over $329,000,000,000 was spent on prescription drugs in the
United States (U.S.). 1 The Centers for Disease Control (CDC) estimates that
almost fifty percent of the U.S. population has utilized a prescription drug in
the preceding month, 2 and many infants in the U.S. today receive a
prescription medication just minutes after birth. 3 Today, pharmacy
professionals utilize their advanced training, knowledge of evidence-based
medicine, and other technical and computer-based programs to help ensure that
pharmaceutical drugs are delivered safely to patients. Therefore, pharmacy
professionals are held to high standards by multiple government and private
accreditation agencies; 4 however, even with these practical safeguards and
agency regulations, there are still areas of pharmacy that are susceptible to
endangering public health. After all, it takes just one negligent pharmacy to
poison the public’s trust. The New England Compounding Center’s (NECC)
pharmacy operation was one such case. 5
In one of the worst pharmaceutical tragedies, a single compounding
pharmacy was responsible for more than 438 cases of fungal meningitis and
thirty-two deaths in the span of fewer than two months, a number that would
grow over the next year. 6 In 2012, NECC, located in Framingham,
Massachusetts, manufactured and sold thousands of vials of a bacterially
contaminated steroid solution to physicians for treatments of patients across
the country. 7 This tragedy, however, was preventable. Lax inspections, failure
to appropriately follow up on concerns about the inherent and associated risks
of drug compounding, and failures in regulatory standards were all
contributing factors. 8 For instance, the Federal Food and Drug Administration

1. IMS INST. FOR HEALTHCARE INFORMATICS, MEDICINE USE AND SHIFTING COSTS OF
HEALTHCARE: A REVIEW OF THE USE OF MEDICINES IN THE UNITED STATES IN 2013 30 (2014).
2. See CTRS. FOR DISEASE CONTROL & PREVENTION, HEALTH, UNITED STATES, 2013 21
(2014).
3. See Carol A. Miller et al., Controversies Concerning Vitamin K and the Newborn, 112
PEDIATRICS 191, 191 (2003).
4. See generally ACCREDITATION COUNCIL FOR PHARMACY EDUC., ACCREDITATION
STANDARDS AND KEY ELEMENTS FOR THE PROFESSIONAL PROGRAM IN PHARMACY LEADING
TO THE DOCTOR OF PHARMACY DEGREE iii (2015).
5. See generally Mary A. O’Connor, The New England Compounding Center, J. LEGAL
NURSE CONSULTING, Spring 2013, 1, 39.
6. Pharmacy Compounding: Implications of the 2012 Meningitis Outbreak: Hearing Before
the S. Comm. on Health, Educ., Labor & Pensions, 112th Cong. (2012) (statement of Margaret A.
Hamburg, Commissioner of Food & Drugs, Food & Drug Administration), http://www.fda.gov/
NewsEvents/Testimony/ucm327667.htm [hereinafter Hamburg Testimony].
7. Id.; see also Multistate Outbreak of Fungal Meningitis and Other Infections, CTRS. FOR
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/hai/outbreaks/meningitis.html (last
updated Feb. 18, 2016).
8. See O’Connor, supra note 5, at 39.
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(FDA) inspected NECC in 2002, 9 issued a warning letter in 2006, 10 and held
these concerns about the pharmacy’s actions until the tragedy was
discovered. 11 However, the Massachusetts State Board of Pharmacy’s (MSBP)
2011 inspection of NECC found their sterile processing areas to be
“[s]atisfactory.” 12 Despite “inspections” and continued complaints about
NECC, action that could have prevented this tragedy was not taken. 13 The
NECC tragedy highlights just one of many examples that gives patients alarm
and grounds for stricter regulatory processes and more thorough inspections.
Pharmaceutical compounding is the process by “which a licensed
pharmacist, a licensed physician, or, in the case of an outsourcing facility, a
person under the supervision of a licensed pharmacist, combines, mixes, or
alters ingredients of a drug to create a medication tailored to the needs of an
individual patient.” 14 Furthermore, compounds are divided into two categories
within the profession: non-sterile and sterile compounds. 15 Compounds that are
considered non-sterile are preparations like oral liquids, tablets, topical creams
and gels, suppositories, and troches. 16 Non-sterile compounds require
procedures to prevent the risk of outside contaminants; however, they do not
need to be performed in a truly sterile (or bacteria/fungal free) environment. 17
On the other hand, sterile compounded products need to be completely free of
bacteria and other endotoxins, which if present may cause infection or disease
to the patient. 18 Sterile compounds require complex operating procedures,
expensive facilities and equipment, and skillful and meticulous manipulations
carried out by compounding personnel to ensure safety and efficacy.

9. H.R. COMM. ON ENERGY & COMMERCE, 113TH CONG., FDA’S OVERSIGHT OF NECC
7 (2013).
10. Id. at 10.
11. Id. at 39.
12. Hamburg Testimony, supra note 6; see also THE COMMONWEALTH OF MASS. DEP’T OF
PUB. HEALTH, NEW ENGLAND COMPOUNDING PHARMACY, INC. (NEW ENGLAND
COMPOUNDING CENTER) – INSPECTION REPORT, DATED 5/24/11 (2011).
13. See generally H.R. COMM. ON ENERGY & COMMERCE, supra note 9.
14. Compounding and the FDA: Questions and Answers, FOOD & DRUG ADMIN.,
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/
ucm339764.htm (last updated Oct. 6, 2015).
15. Frequently Asked Questions About Pharmaceutical Compounding, AM. PHARMACISTS
ASS’N, http://www.pharmacist.com/frequently-asked-questions-about-pharmaceutical-com
pounding (last updated Nov. 19, 2012).
16. BONNIE S. BACHENHEIMER, AM. SOC’Y OF HEALTH-SYSTEM PHARMACISTS, MANUAL
FOR PHARMACY TECHNICIANS 369-73 (4th ed. 2011). Troches are a type of gelatin dissolving
tablet that you place in your mouth and allow to “melt.” Id. at 372.
17. See <795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS, U.S.
PHARMACOPEIAL CONVENTION, USP38-NF33, 2-3, 4 (U.S. Pharmacopeial Convention 2015).
18. See id.
AND AMERIDOSE: A HISTORY OF MISSED OPPORTUNITIES?
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According to 2003 estimates by the FDA, only one percent of prescriptions
were compounded in the U.S. 19 While that number is most likely outdated due
to the surge in bio-identical hormone replacement, manufacturer shortages, and
other consumer pushes for compounded medication, even one percent of retail
only prescriptions in 2014 would be equivalent to around forty million
prescriptions. 20 This number also does not include prescriptions compounded
in a hospital, a doctor’s office, or those compounded in a retail setting and sold
to the hospital, which could ultimately double the final tally. 21 More recently,
the National Community Pharmacists Association (NCPA) 22 conducted a
national survey of independent community pharmacies in November 2012. 23
Results showed that seventy-two percent of those pharmacies engaged in
compounding provided non-sterile compounding services only; thirty-eight
percent of the pharmacies compounded five percent or more of their total
prescription count. 24 Extrapolating this to the more than 23,000 pharmacies
NCPA represents, 25 it is clear that compounding is prevalent in the practice of
pharmacy.
Compounding pharmacy has been historically overlooked by federal
agencies and gained differing levels of enforcement from state boards of
pharmacy (SBOP). However, in response to the 2012 NECC tragedy, Congress

19. Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the
Right Mix to Protect Patients: Hearing Before the S. Comm. on Health, Educ., Labor & Pensions,
108th Cong. (2003) (statement of Steven K. Galson, Acting Director, Center for Drug Evaluation
& Research, Food & Drug Administration); What is Compounding?, INT’L ACAD.
COMPOUNDING PHARMACISTS, http://www.iacprx.org/default.asp?page=1 (last visited Mar. 3,
2016).
20. It is estimated that four billion retail prescriptions were filled in 2014. State Health
Facts: Total Number of Retail Prescription Drugs Filled at Pharmacies, KAISER FAM. FOUND.,
http://kff.org/other/state-indicator/total-retail-rx-drugs/ (last visited Jan. 8, 2016).
21. Id.
Data shown here are for calendar year 2014 and include the number of prescription drugs
filled at retail pharmacies only. Data are based on IMS’s Vector One® database which
collects data from a panel of retail pharmacies, third party payers, and data providers.
Retail pharmacies include independent pharmacies, chain pharmacies, food stores, and
mass merchandisers found in 814 defined regional zones. These totals include
prescriptions filled at pharmacies only and a small portion of over-the-counter
medications and repackagers and exclude those filled by mail order.
Id.
22. “NCPA represents the interests of pharmacist owners, managers, and employees of more
than 23,000 independent community pharmacies across the United States. Independent
community pharmacies dispense approximately 40% of the nation’s retail prescription drugs.”
NAT’L CMTY. PHARMACISTS ASS’N, Community Pharmacy Compounding Survey November
2012 (2012), http://www.ncpanet.org/pdf/Survey-compounding-results.pdf.
23. Id.
24. Id.
25. Id.
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focused attention on compounding and passed the Drug Quality and Security
Act (DQSA) a year later. 26 The Act implements important changes to the
nature of pharmacy regulation, but it is incomplete. Its reactive response
misses real opportunities that could ensure a NECC-type tragedy will not
happen again and leaves uncertainty in nationwide enforcement of
compounding pharmacy.
The goal of this comment is to analyze and address the holes in the
regulation of compounding pharmacy that ensure product quality and patient
safety, and to identify Congress’s missed opportunities in the passage of the
DQSA. Section I of this comment is an introduction into pharmaceutical
compounding. Section II of this comment begins by briefly describing the
origins of pharmaceutical compounding, followed by Section III, which
describes some of the most likely ways compounds may be incorrectly
prepared and result in harm to patients. Section IV then discusses regulatory
authority and past enforcement of compounding on the federal and state levels.
Section V then analyzes a part of the DQSA that is intended to regulate
compounding and the registration process it creates for sterile compounders.
Section VI points out regulatory failures and the issues not addressed, or
missed in legislating the DQSA. The comment will then conclude with Section
VII, discussing possible remedies and actions that state and federal agencies
may take to increase compounding quality and safety.
II. A BRIEF HISTORY OF COMPOUNDING
The art of compounding originated in ancient Egyptian and Roman times
when healers mixed herbs, roots, and other ingredients to make remedies
intended to cure illnesses faced by their community. 27 Some remedies were
naturally successful, while others caused harm to the patient. 28 As
understanding of these remedies progressed, the process was formalized into
the profession of pharmacy. 29 The profession started like many others, where
pharmacists trained as apprentices, but then a curriculum of pharmacy was
later formalized into a higher education setting. 30 In 1820, the newly founded

26. See Drug Quality and Security Act, Pub. L. No. 113-54, 127 Stat. 587 (2013)
[hereinafter Drug Quality and Security Act].
27. See generally Edward Kremers, KREMERS AND URDANG’S HISTORY OF PHARMACY 3
(Glenn Sonnedecker ed., 4th ed. 1976); see also DAVID L. COWEN & WILLIAM H. HELFAND,
PHARMACY: AN ILLUSTRATED HISTORY 23 (Harry N. Abrams ed., 1990).
28. See generally COWEN & HELFAND, supra note 27.
29. See generally id.
30. Joseph L. Fink, Pharmacy: A Brief History of the Profession, STUDENT DR. NETWORK
(Jan. 11, 2012), http://www.studentdoctor.net/2012/01/pharmacy-a-brief-history-of-the-profes
sion/. The first school of pharmacy was founded in Philadelphia in 1821. Id. Originally, students
could obtain a Graduate in Pharmacy (Ph.G.) degree with only fifty-two total weeks of study or a
Pharmaceutical Chemist (Ph.C.) degree after seventy-two weeks. Id. Eventually the standard
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U.S. Pharmacopeia Convention established a book known as the United States
Pharmacopeia (USP), which served as a reference for information about
chemicals “most fully established and best understood.” 31 Pharmacists used the
USP as one of several aids to prepare and manipulate medications from raw
drug chemicals into prescription drugs. 32 This preparation, commonly known
as compounding, accounted for most medication before the 1950’s, including
prescriptions written by doctors and those created independently when patients
secured remedies straight from the pharmacist. 33 Beginning in the late 1950’s
and early 1960’s, the large scale manufacturers began to push the role of
pharmacists away from compounding to dispensing commercially
manufactured drugs as more patients were starting treatments for chronic and
quickly diagnosable acute diseases. 34 By 1990, nearly all over-the-counter
drugs and prescription medications were commercially manufactured rather
than compounded in the corner drugstores leading to enhanced regulatory
power of the FDA to ensure uniformity and quality of medications. 35 The
move to manufactured medications also allowed the industry to provide mass
treatments of many medical conditions, and spurred research and development
of other drugs not at the time listed in the USP.

became a four-year Bachelor of Science in Pharmacy (B.S.Pharm.), and as of the 1990’s, the only
degree qualifying a student to become licensed as a pharmacist is the Doctorate of Pharmacy
degree (Pharm.D). Id.
31. USP Our History, U.S. PHARMACOPEIAL CONVENTION, http://www.usp.org/about-usp/
our-history/usp-milestones-timeline (last visited Feb. 10, 2015). The USP may also be referred to
by others as the USP-NF or the USPDI. In 1975, the USP purchased the National Formulary from
the American Pharmacists Association and changed the name to USP-NF. Id. Before 1975, the
National Formulary (NF) was a separate guidebook that contained information on the properties
of herbs, roots, and other chemicals that had medicinal properties. Id. For purposes of this article
the term USP and USP-NF will be used interchangeably as practitioners commonly do. Id.
32. See GEETA TIRUMALAI & ANGELA LONG, UNITED STATES PHARMACOPEIAL
CONVENTION: RESPECTING THE PAST, MOVING CONFIDENTLY INTO THE FUTURE (2013),
http://www.usp.org/sites/default/files/usp_pdf/EN/aboutUSP/usp_history_final_with_acknowl
edgement.pdf.
33. Peter Younkin, Making the Market: How the American Pharmaceutical Industry
Transformed Itself in the 1940s 1, 5 (Nov. 2008) (unpublished manuscript), http://faculty.chicago
booth.edu/workshops/orgs-markets/past/more/pdf/YounkinJan09.pdf. See generally DurhamHumphrey Amendment, Pub. L. No. 215, 65 Stat. 648 (amending §§ 303 (c) and 503(b) of the
Federal Food, Drug, and Cosmetic Act, codified in scattered sections of Title 21 U.S.C.); Virgil
Van Dusen & Alan R. Spies, A Review of Federal Legislation Affecting Pharmacy Practice,
PHARMACY TIMES (Dec. 1, 2006), http://www.pharmacytimes.com/publications/issue/2006/2006
-12/2006-12-6154.
34. See Jesse M. Boodoo, Compounding Problems and Compounding Confusion: Federal
Regulation of Compounded Drug Products and the FDAMA Circuit Split, 36 AM. J. L. & MED.
220, 222 (2010).
35. Id. at 221-22.
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However, the art of compounding medications was never completely lost
by the pharmacy profession. In 1981, Professional Compounding Centers of
America (PCCA) was created with the goal of reviving the practice of
compounding to the profession. 36 Doctor and patient demands for medications
free of potential allergens (due to additives), medications requiring specific
dosage forms (large pills to liquids), and specialized dosages of medications
not commercially available, all contributed to the re-growth of compounding in
the practice of pharmacy. 37
With the revitalization of compounding there came a new categorization of
compounding pharmacy. Compounders in the business were now viewed as
falling into one of two categories: traditional compounders or non-traditional
(or pirate manufacturing) compounders. 38 Traditional compounders were those
pharmacists who prepared just enough of a patient specific compound or
sometimes made a little extra in anticipation of prescribing patterns from local
doctors. 39 Compounders that stretched this “anticipatory need” and made
excessive quantities of medications were categorized as non-traditional, or
“pirate-manufacturers.” 40 These non-traditional compounding pharmacies
grew more numerous and eventually large quantities of compounded drugs
were regularly shipped to patients across the U.S. instead of being dispensed to
their local communities. Coupled with a spur in the understanding of hormone
replacement therapy (HRT) in the 1990’s and early 2000’s, further demands
for compounding produced lucrative business ventures for pharmacists because
not many HRT drugs were commercially available in specific dosages. 41 This
niche attracted new attention to the practice of compounding and created
questions regarding large-scaled compounding safety and legality.
III. THE RISKS AND CURRENT SAFETY MEASURES IN COMPOUNDING
MEDICATIONS
There are inherent risks associated with unregulated and poor quality
compounding. Compounding is both art and science and may pose serious
patient safety risks if not executed properly. The risks that compounders most
commonly encounter are those surrounding potency, contamination,

36. Prof’l Compounding Ctrs. of Am., What is PCCA?, http://www.pccarx.com/patients/
what-is-pcca-patients (last visited Jan. 31, 2016).
37. See Tamira Mullarkey, Pharmacy Compounding of High-Risk Level Products and
Patient Safety, 66 AM. J. HEALTH-SYS. PHARM. S4, S4-S5 (2009).
38. See Boodoo, supra note 34, at 229-30.
39. See id. at 223-34.
40. Id. at 229.
41. Bruce Patsner, Pharmacy Compounding of Bioidentical Hormone Replacement Therapy
(BHRT): A Proposed New Approach to Justify FDA Regulation of These Prescription Drugs, 63
FOOD & DRUG L.J. 459, 459 (2008).
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overmedication, and medication-replacement. 42 These risks are also intensified
when compounders produce mass quantities—as larger batches usually equal
larger errors. 43 “Unlike [commercial] drug manufacturers who are required to
demonstrate the safety, efficacy, strength, quality, and purity of their proposed
products via the FDA’s New Drug Application, drug compounders design and
distribute their products easily and unrestrictedly . . . without pre- or postmarket testing.” 44 The FDA acknowledges that the average pharmacist
compounding a drug product does not have to adhere to Current Good
Manufacturing Practices (CGMP) 45 that drug manufacturers must adhere to, 46
however, compounders must adhere to the safeguards set forth in the USP’s
general chapters. 47 CGMPs help to curtail the five most common risks to
patients when preparing large-scale drug products, but similarly, traditional

42. Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the
Right Mix to Protect Patients: Hearing Before the S. Comm. on Health, Educ., Labor & Pensions,
108th Cong. (2003) (statement of Sarah Sellers, Executive Director, The Center for
Pharmaceutical Safety); Boodoo, supra note 34, at 225.
43. Id. at 230.
44. Id. at 225.
45. Id.
CGMPs provide for systems that assure proper design, monitoring, and control of
manufacturing processes and facilities. Adherence to the CGMP regulations assures the
identity, strength, quality, and purity of drug products by requiring that manufacturers of
medications adequately control manufacturing operations. This includes establishing
strong quality management systems, obtaining appropriate quality raw materials,
establishing robust operating procedures, detecting and investigating product quality
deviations, and maintaining reliable testing laboratories. This formal system of controls at
a pharmaceutical company, if adequately put into practice, helps to prevent instances of
contamination, mix-ups, deviations, failures, and errors. This assures that drug products
meet their quality standards.
Facts About the Current Good Manufacturing Practices (CGMPs), FOOD & DRUG ADMIN.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm169105.htm (last
visited Feb. 17, 2015).
46. See generally FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: CURRENT GOOD
MANUFACTURING PRACTICE – INTERIM GUIDANCE FOR HUMAN DRUG COMPOUNDING
OUTSOURCING FACILITIES UNDER SECTION 503B OF THE FD&C ACT (2014); Drug Applications
and Current Good Manufacturing Practice (CGMP) Regulations, FOOD & DRUG
ADMIN., http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm0900
16.htm (last updated Dec. 17, 2014).
47. USP General chapters below <1000> are considered requirements, while those chapters
above <1000> are considered suggested practices. USP <795> (covering non-sterile
compounding) and USP <797> (covering sterile compounding) are the standards in which
traditional compounding pharmacists are to use when preparing compounding medications. These
practices include ensuring the proper storage of chemicals, using proper production devices,
implementing quality controls on sterility and potency, etc. U.S. PHARMACOPEIAL CONVENTION,
U.S PHARMACOPEIA – NATIONAL FORMULARY 3 (34th ed. 2011).
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compounders (likely lower-volume producers) can avoid these risks with strict
adherence to the USP guidelines.
A.

Potency

A compounded drug product is said to have an acceptable potency when a
test indicates that there is ninety to 110% of the labeled strength of every
active pharmaceutical ingredient (API) in the preparation. 48 Therefore an
acceptably “potent” commercially manufactured or compounded drug may
contain fluctuations in API content, however, potency outside this range labels
the drug to be either sub- or superpotent. 49
The FDA is aware of potency issues and has conducted several studies of
compounded drug products over the years, including a survey in 2001 and
another in 2006. 50 Both FDA surveys noted that about one-third of
compounded medications were outside of the accepted potency ranges
federally recognized by the USP. 51 A majority of those compounds tested
included drugs containing hormones, drugs for inhalation, and local anesthetic
products—the outliers ranged in potency from less than seventy percent to
more than 260% of their labeled value. 52 These tests demonstrate a need for
concern as taking any medication that is two to three times more potent than
prescribed and labeled can pose serious problems and unwanted side effects. 53
Compounders that use drugs with narrow therapeutic indices 54 could therefore
cause potentially deadly consequences when double or triple dosed. For
instance, patients could experience arrhythmias and seizures if taking a

48. Press Release, Updated FDA Statement on Compounded Versions of
Hydroxyprogesterone Caproate (the active ingredient in Makena) (June 15, 2012).
49. See id.
50. Galson, supra note 19; 2006 Limited Survey of Compounded Drug Products, FOOD &
DRUG ADMIN., http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Phar
macyCompounding/ucm204237.htm (last updated Mar. 22, 2010) [hereinafter 2006 Limited
Survey].
51. See 2006 Limited Survey, supra note 50; USP-NF, U.S. PHARMACOPEIAL CONVENTION
(2016), http://www.usp.org/usp-nf (“The U.S. Federal Food, Drug, and Cosmetics Act designates
the USP-NF as official compendia for drugs marketed in the United States. A drug product in the
U.S. market must conform to the standards in USP–NF to avoid possible charges of adulteration
and misbranding.”).
52. 2006 Limited Survey, supra note 50. These products tested included both sterile and nonsterile compounds. Id.
53. See generally id.
54. A drug with a narrow therapeutic index is a drug in which:
there is less than a 2-fold difference in median lethal dose (LD50) and median effective
dose (ED50) values, or have less than a 2-fold difference in the minimum toxic
concentrations and the minimum effective concentrations in the blood and safe and
effective use of the drug products requires careful dosage titration and patient monitoring.
21 C.F.R. § 320.33(c) (2015).
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compounded theophylline capsule that is actually three times the labeled
potency. 55 However, pharmacists have many ways to overcome drug potency
problems. Utilizing only chemicals stored properly and within the expiration
date, ensuring precise measurements of all ingredients, developing and
implementing quality control standards, 56 and utilizing outside laboratories 57 to
test product potency, are all highly recommended in the practice and
encouraged by the USP standards. 58
However, despite the known problems associated with potency in
compounded medications, potency testing is not required for all compounded
products under USP or FDA guidelines for compounders as it could unduly
burden the pharmacy. 59 Moreover, because of the cost, 60 some pharmacies may
skip this step and seldom check any potencies, while other pharmacies are
required to test as part of their independent accreditations. 61 For example, the
Pharmaceutical Compounding Accreditation Board (PCAB) requires, among
many other compounding safeguards, accredited pharmacies to show evidence
that one preparation per dosage form was tested for potency every six months
as a quality control measure. 62 While it may seem like a minimal standard,
consistent potency testing of randomized products allows traditional
pharmacies to identify potential problems in procedure and maximize
processes to ensure patient safety. Regardless of the price, compounders

55. Theophyllines, DRUGS.COM (2016), http://www.drugs.com/monograph/theophy
llines.html.
56. See <795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS, U.S.
PHARMACOPEIAL CONVENTION, supra note 17, at 5, 8. Standardized compounding practices and
formulas are essential guidelines for technicians and pharmacists who engage in compounding.
Id. at 1. These help to provide standardization at each pharmacy. Id.
57. Loyd V. Allen, Potency and Stability Testing, SCI. & TECH. (2013), https://compound
ingtoday.com/Newsletter/Science_and_Tech_1303.cfm. Potency testing can be performed
through a number of outside laboratories. See, e.g., Bill J. Zolner, Stating a Testing Program,
EAGLE ANALYTICAL SERVS., http://www.eagleanalytical.com/sitecontent/590/featured-vide
os.aspx (last visited Feb. 10, 2015) (recommending that you test five percent monthly of
compounds for quality control).
58. See <795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS, U.S.
PHARMACOPEIAL CONVENTION, supra note 17, at 7.
59. See generally id.; <797> PHARMACEUTICAL COMPOUNDING—STERILE PREPARATIONS,
U.S. PHARMACOPEIAL CONVENTION, USP38-NF33 (U.S. Pharmacopeial Convention 2015)
(stating that sterile compounds need to be tested according to <71> Sterility Tests).
60. Potency tests generally start around $160 and can run upwards from there depending on
the amount of ingredients in the preparation. See, e.g., Invoice from Dynalabs to Tri-State
Compounding Pharmacy, LLC (Dec. 17, 2015) (on file with author).
61. PHARMACY COMPOUNDING ACCREDITATION BD., PCAB ACCREDITATION MANUAL 33
(2011) [hereinafter PCAB ACCREDITATION MANUAL].
62. Id. at 17, 47 (dosage forms may include capsules, troches, gels, creams, ointments,
solutions, etc.).
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should consider that mistakes resulting in patients being over- or under-dosed
can harm patients and lead to compounder liability. 63
B.

Contamination

As the NECC meningitis outbreak demonstrated, contamination is another
potentially harmful and deadly risk associated with compounding although it is
mostly an issue for sterile products. 64 In 2012, the FDA was notified of a
“cluster of meningitis cases at a single clinic” by the Tennessee Department of
Health. 65 The FDA’s investigation of NECC showed fungal contamination in
the steroid injections from NECC and issued a MedWatch Safety Alert to over
220,000 health professionals on October 5, 2012. 66 At the time of Margaret
Hamburg’s testimony before the U.S. Senate on November 15, 2012, the CDC
had reported thirty-two deaths in 438 cases of meningitis and peripheral joint
infections across nineteen states. 67 That number continued to grow in the
months to follow reaching 751 reported cases and sixty-four deaths. 68
Furthermore, the Massachusetts Department of Public Health and FDA joint
investigation and inspection noted a slew of USP violations. 69
USP guidelines for sterile preparations allow compounders to greatly
reduce the risk of contamination, yet sometimes these guidelines are
overlooked for cost and technical challenges of implementation. 70 However,
the USP requires that sterile compounded products are tested for contamination
and provides certain benchmarks for compounders. 71 Unfortunately, because
sterile drug compounds can be highly lucrative, it is not unusual for
pharmacies to make a batch of sterile compounds, or in NECC’s case—

63. Boodoo, supra note 34, at 225-26 (stating that a patient was admitted to the hospital for
twenty-five days when he ingested a compounded capsule containing over 1000% of the labeled
API in it).
64. Hamburg Testimony, supra note 6.
65. Id.
66. Id.
67. Id.
68. Press Release, Dep’t of Justice, 14 Indicted in Connection with New England
Compounding Center and Nationwide Fungal Meningitis Outbreak (2014), http://www.justice.
gov/opa/pr/14-indicted-connection-new-england-compounding-center-and-nationwide-fungalmeningitis.
69. See MASS. DEP’T OF PUB. HEALTH, NEW ENGLAND COMPOUNDING CENTER (NECC)
PRELIMINARY INVESTIGATION FINDINGS 4 (2012).
70. See generally <795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS,
U.S. PHARMACOPEIAL CONVENTION, supra note 17.
71. See generally <71> STERILITY TESTS, U.S. PHARMACOPEIAL CONVENTION, USP38NF33, 125 (U.S. Pharmacopeial Convention 2015). See also <797> PHARMACEUTICAL
COMPOUNDING—STERILE PREPARATIONS, supra note 59.
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hundreds of batches, without the proper equipment, procedures, or testing of
finished drug products. 72
C. Overmedication and Medication Replacement
Overmedication may occur when a physician prescribes an excessive
amount of a medication or prescribes an altogether unnecessary medication. 73
Most of the time, prescriptions resulting in overmedication or inappropriate
medication replacement are due to patient requests, 74 and the physician or
pharmacist is either unaware of other medications the patient is taking, or what
interactions occur between commercially manufactured and compounded
medications. 75 Overmedication can also occur when a patient uses too much of
a medication, intentionally or unintentionally, or if a pharmacist incorrectly
counsels or fills the medication. 76 Prescription verification and reconciliation
procedures allow a pharmacist to recognize the danger to the patient; however,
the pharmacist must be trained in advanced compounding practices to
understand just how much of the drug the patient is absorbing via a specific
cream, capsule, etc. Medication-replacement has also become one way patients
are trying to obtain natural (preservative free or non-commercial) remedies as a
substitute for manufactured products and thus leading to a growth in
compounding. 77 Sometimes these “natural” remedies are untested, composed
of drugs with no monograph, and have completely bypassed any FDA safety
process. 78
Stewardship of the technical skills and education of advanced
compounding practices allows compounders to overcome these challenges. A
compounder’s commitment to ongoing evaluation of pharmacy processes and
safeguards is therefore critical to keeping patients safe even with great
financial incentives to compound and build business fast. However, not all
compounders follow these practices—partially because pharmacies slip under
the regulatory radar of state boards or federal agencies. Moreover, some

72. Endotoxin and sterility tests combined run about $160 per tested substance. Invoice,
Dyna-Labs, Inc., Dyna-labs Pricing Guide (2014) (on file with author). Depending on the risk
level of the compounded sterile product, USP <797> generally requires sterility and endotoxin
testing for certain high-risk compounded sterile products in multi-use vials, batches greater than
twenty-five single-dose packages, or those exposed to periods of non-refrigeration. See <797>
PHARMACEUTICAL COMPOUNDING—STERILE PREPARATIONS, U.S. PHARMACOPEIAL
CONVENTION, supra note 59, at 575.
73. Boodoo, supra note 34, at 228.
74. John McKinlay et al., Effects of Patient Medication Requests on Physician Prescribing
Behavior: Results of a Factorial Experiment, 52 MED. CARE 4, 294, 298 (2014).
75. Boodoo, supra note 34, at 228.
76. Id. at 225.
77. See id. at 228.
78. Id. at 228-29.
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pharmacies have grown too fast, out-pacing safety and quality standards, or
have been too greedy, skimping on expensive quality controls. While demand
for compounded drug products continues to rise, compounders must ensure
they take the proper safeguards in this “lax” regulatory environment or patient
harm and compounding failures will continue to increase.
IV. FEDERAL REGULATION AFFECTING PHARMACY PRIOR TO THE DQSA
A.

Federal Regulation of Medications for Patient Use

The origins of FDA oversight in pharmaceutical products grew from the
Pure Food and Drug Act of 1906 (PFDA). 79 The bill created federal executive
authority in an agency to prevent adulterated and misbranded food, drugs, and
medication from being manufactured and sold within the U.S. 80 However, in
1937, it became clear that the PFDA was not enough when a company
manufacturing sulfanilamide elixir killed over 100 people across the U.S. 81
Congress re-evaluated the PFDA and subsequently passed the Federal Food,
Drug, and Cosmetic Act (FDCA) in 1938. 82 The FDCA then introduced more
FDA oversight and regulation of new drug products being made and sold in the
U.S. 83
The FDCA required manufacturers of “new drugs” to obtain premarket
approval from the FDA for products intended for the mass market. 84 To define
what “new” was, the Act adopted the list of drugs in the current USP, however,
it made no mention on whether combining two old drugs constituted a new
drug. 85 As such, manufacturers and compounders continued producing
combinations of USP listed products without going through the “new drug”

79. John Swann, FDA’s Origin, FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/
WhatWeDo/History/Origin/ucm124403.htm (last updated June 24, 2014).
80. Federal Food and Drugs Act of 1906, Pub. L. No. 59-384, 34 Stat. 768 (1906) (deriving
federal authority from the Commerce Clause).
81. See generally Carol Ballentine, Taste of Raspberries, Taste of Death: The 1937 Elixir
Sulfanilamide Incident, FDA CONSUMER MAG., June 1981, http://www.fda.gov/aboutfda/what
wedo/history/productregulation/sulfanilamidedisaster/default.htm. Sulfanilamide was used to
treat streptococcal infections and was marketed in powder and tablet form, however, due to
demand for a liquid dosage form, the company experimented and ultimately used diethylene
glycol, a component of antifreeze, an unknowingly toxic agent, to dissolve the powder and
labeled it an elixir (alcoholic compound). Id. Although a pharmacist formulated the product, it
was not tested, and it led to a public health disaster. Id.
82. Id.
83. Id.
84. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(a) (2012); see also Michael
Snow, Seeing Through the Murky Vial: Does the FDA Have the Authority to Stop Compounding
Pharmacies from Pirate Manufacturing?, 66 VAND. L. REV. 1609, 1615 (2013).
85. See generally, 21 U.S.C. §§ 351-360ccc-2 (2012).
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pre-market approval process. 86 Under the Act, the FDA had broad authority
over all types of drug production, even traditional pharmacies, although it was
Congress’s primary intent, and the FDA’s understanding, that FDCA was
aimed to prevent large-scale manufacturers of medications, such as the
company producing sulfanilamide, from marketing drugs without approval. 87
However, the FDCA did not expressly carve out the traditional pharmacy
practice of compounding, something that would prove troublesome to future
compounders in understanding the FDA’s actual authority over traditional
pharmacies. 88
For years, the regulation of pharmaceuticals went largely untouched and
unchallenged, until Congress again passed the Kefauver-Harris Amendments
in 1962 (1962 Amendments). 89 The 1962 Amendments modified the FDCA to
require substantial evidence that drugs were safe and effective before being
placed into the market. 90 Equally as important to compounders was the 1962
Amendments notation that the “traditional practice” of compounding in
pharmacies was exempted, and, therefore, traditional compounders did not
need to prove safety and efficacy in compounding to be in compliance with the
FDCA. 91 While the “traditional practice” of compounding was most likely
understood as applying to individualized patient prescriptions, its vagueness
again left regulatory holes that allowed for rapid, but unchecked growth by the
compounding industry.
1. Compounds as New Drugs
After the 1962 Amendments, the FDA continued its focus on
manufacturing and remained largely inactive in its regulation of
compounding. 92 However, a further clarification of what was considered a
“new drug” under the FDCA brought forth new views of regulation on
compounders. 93
86. See Snow, supra note 84, at 1612.
87. See generally id. at 1615.
88. Id.
89. Kefauver-Harris Amendments, Pub. L. No. 87-781, 76 Stat. 780 (1962) [hereinafter 1962
Amendments]; see also Suzanne Junod, FDA and Clinical Drug Trials: A Short History, FOOD &
DRUG ADMIN. (2014), http://www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm30
4485.htm.
90. See DEP’T OF HEALTH & HUMAN SERVS., GUIDANCE FOR INDUSTRY PROVIDING
CLINICAL EVIDENCE OF EFFECTIVENESS FOR HUMAN DRUGS AND BIOLOGICAL PRODUCTS 1
(1998), http://www.fda.gov/downloads/Drugs/GuidanceCompliance%20RegulatoryInformation/
Guidances/UCM078749.pdf+Providing+clinical+evidence+of+effectiveness+for+human+and+
bio&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&ie=
UTF-8&access=p&oe=UTF-8. See generally 1962 Amendments, supra note 89.
91. See generally 1962 Amendments, supra note 89, at Part A.
92. Junod, supra note 89.
93. See id.
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Drugs are defined by the FDCA as any “articles recognized in the official
United States Pharmacopeia . . . [that are] intended for use in the diagnosis,
cure, mitigation, treatment or prevention of disease in man or other animals;
and . . . intended to affect the structure or function of the body . . .” 94 With
these words, Congress adopted the USP as the FDA’s official yardstick in
which to measure any chemical drug products. 95 Thus, any new or designed
chemicals used to treat a patient’s condition, or to use past chemicals in ways
previously not listed under its USP monograph, would trigger a designation of
a “new drug” and require review. 96 But still, the definition of “new drug” did
not address whether combining two chemicals already listed in the USP
qualified.
In 1974, the FDA promulgated 21 C.F.R. § 310.3(h)(1)-(2) and clarified
that a drug is “new” even if it is a “combination of two or more substances,
none of which is a new drug.” 97 The FDA further stated, that a changed or
additional substance used in formulating a compound did not necessarily have
to be an active pharmaceutical ingredient, 98 but could be an “excipient, carrier,
coating, or other component.” 99 This formalization signaled that unless the
compounded combination was exactly as listed in the USP (through FDA
approval), down even to inactive ingredients, then the compounded product
was considered a “new drug.”
Shortly after, compounding regained its prevalence in the later parts of the
1980’s and 1990’s, some pharmacies started compounding “new drugs” on a
large scale, outside the traditional patient specific prescription role. 100 The
FDA investigated these pharmacies to find the process of compounding “exact

94. Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, § 675, 52 Stat. 1040 (1938)
(codified at 21 U.S.C. §§ 301-399d (2012)) reprinted in LEGISLATIVE HISTORY OF THE FEDERAL
FOOD DRUG & ACT AND ITS AMENDMENTS 453, 453 (1979).
95. 21 U.S.C. §§ 351-360ccc-2 (2012) supra note 85 (the FDCA grandfathered drug
substances already in the USP); USP-NF, supra note 51; see also USP Milestones—A Timeline,
U.S. PHARMACOPEIAL CONVENTION, http://www.usp.org/about-usp/our-history/usp-milestonestimeline (last visited Mar. 1, 2016) (stating the USP acquired the NF in 1975). USP-NF publishes
a list of drug substances that include monographs, dosage forms, and compounded preparations.
Id. This list is updated as the FDA accepts new formulations and research. Id. See generally
LOYD V. ALLEN, THE ART, SCIENCE, AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING
1-19 (Sandra J. Cannon & Nancy Tarleton Landis eds., 4th ed. 2012).
96. See Med. Ctr. Pharmacy v. Mukasey, 536 F.3d 383, 395 (5th Cir. 2008).
97. 21 C.F.R. § 310.3(h)(1)-(2) (1974).
98. Id. Active pharmaceutical substances are those types of drugs/chemicals that produce a
biological response in an individual for therapeutic purposes set forth. S. Kopp, Definition of
Active Pharmaceutical Ingredient 3-4 (World Health Organization, Working Document
QAS/11.426/Rev.1, 2011).
99. 21 C.F.R. § 310.3(h)(1) (1974).
100. Boodoo, supra note 34, at 232-33.
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copies” of already FDA-approved drugs. 101 In response to the large-scale
compounders, the FDA issued a Compliance Policy Guide (CPG) in 1992 that
reaffirmed their ability to exercise discretionary authority and enforcement
practices over compounding pharmacies. 102 To aid compounders in navigating
FDA enforcement, the 1992 CPG also provided a list of compounding related
activities the FDA would use to assess whether or not a pharmacy was acting
like a manufacturer. 103 Activities included:
1. Soliciting business . . . to compound specific drug products, product classes,
or therapeutic classes of drug products [;] 2. Compounding, regularly, or
inordinate amounts, drug products that are commercially available in the
marketplace and that are essentially generic copies of commercially available,
FDA-approved drug products[;] 3. Receiving, storing, or using drug substances
without first obtaining written assurance from the supplier that each lot of the
drug substance has been made in an FDA approved facility[;] 4. Receiving,
storing, or using drug components not guaranteed or otherwise determined to
meet official compendia requirements[;] 5. Using commercial scale
manufacturing or testing equipment for compounding drug products[;] 6.
Compounding inordinate amounts of drugs in anticipation of receiving
prescriptions in relation to the amounts of drugs compounded after receiving
valid prescriptions[;] 7. Offering compounded drug products at wholesale to
other state licensed persons or commercial entities for resale[;] 8. Distributing
inordinate amounts of compounded products out of state[;] 9. Failing to
operate in conformance with applicable state law regulating the practice of
104
pharmacy.

The FDA also listed possible agency enforcement actions that ranged from
issuance of warning letters to criminal charges. 105 The 1992 CPG received
pushback from several pharmacy associations seeking to eliminate federal
oversight on compounding pharmacies; however, resistance did little but cast
uncertainty on the FDA’s ability to use the 1992 CPG as a tool to aid them in
their historically limited enforcement of compounding. 106

101. See id. at 232.
102. FOOD & DRUG ADMIN., COMPLIANCE POLICY GUIDE FOR FDA STAFF AND INDUSTRY 4
(1992) [hereinafter 1992 CPG]. “[W]hen the scope and nature of a pharmacy’s activity raises the
kinds of concerns normally associated with a manufacturer and results in significant violations of
the new drug, adulteration, or misbranding provisions of the [FDCA], FDA has determined that it
should seriously consider enforcement action.” Id.
103. See id. at 4-5.
104. Id. at 5; Snow, supra note 84, at 1616-17; Boodoo, supra note 34, at 233.
105. 1992 CPG, supra note 102, at 6.
106. Snow, supra note 84, at 1616-18.
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2. Food and Drug Administration Modernization Act
In 1997, Congress again modified parts of the 1938 FDCA by passing the
Food and Drug Administration Modernization Act (FDAMA). 107 Most
notably, the FDAMA added Section 503A to the FDCA and created a specific
section related to pharmacy compounding. 108 The FDAMA stated a limited
number of FDCA provisions 109 would not apply to compounding pharmacies
that met the requirements of Section 503A. 110 Therefore, the FDAMA created
a formal exemption for compounders to the “new drug” review process. 111
The exemption requirements under FDAMA were merely a formal
adaptation of the 1992 CPG and provided three concepts for compounders to
follow. 112 The FDAMA specifically exempted compounds from FDA
oversight if the compounds that were produced were: (1) patient specific and
pursuant to a prescription; (2) limited to anticipatory compounding based on an
established pharmacist-physician relationship; (3) and if the pharmacy [did]
not distribute more than five percent of [its] total prescription orders . . . out of
state. 113
However, the FDAMA was not the FDA’s silver bullet of clarity for
compounding and was almost immediately challenged by pharmacies claiming
the marketing prohibition infringed on compounders rights under the First
Amendment. 114 On this challenge, the Ninth Circuit invalidated 503A in its
entirety in the precursor case to Western States Medical Center v. Shalala. 115
The Supreme Court granted certiorari in Thompson v. Western States Medical
Center and upheld the unconstitutional nature of the marketing prohibition, but
did not rule on the severability of the section from 503A in its entirety 116
causing a circuit split. 117 Therefore, 503A was invalid in the Ninth Circuit, 118
but other circuits continued to uphold 503A as valid—striking only the

107. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, § 127,
111 Stat. 2296, 2328 (1997) (codified at 21 U.S.C. § 353a (2012)) [hereinafter FDAMA]; Snow,
supra note 84, at 1618.
108. FDAMA, supra note 107, at § 503A; Snow, supra note 84, at 1619.
109. FDAMA, supra note 107, at § 503A (referencing Sections 501(a)(2)(B), 502(f)(1), and
505 of the FDCA).
110. Id.
111. See id.
112. See FDAMA, supra note 107, at § 503A; see also Galson, supra note 19.
113. See FDAMA, supra note 107, at § 503A; Snow, supra note 84, at 1619.
114. W. States Med. Ctr. v. Shalala, 238 F.3d 1090, 1093 (9th Cir. 2000).
115. Id. at 1097-98. The court found the marketing prohibition was not severable and
therefore the entire act was invalid. Id. at 1098.
116. Thompson v. W. States Med. Ctr., 535 U.S. 357, 360 (2002).
117. Compare Shalala, 238 F.3d at 1098, with Med. Ctr. Pharmacy v. Mukasey, 536 F.3d.
383, 409 (5th Cir. 2008).
118. Shalala, 238 F.3d at 1098.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

346

SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY

[Vol. 9:329

provision related to marketing activities. 119 Aside from the challenges and
split, the FDA could still have reverted to the definition of “new drugs” in
compounding enforcement actions to maintain their authority. 120
Upon the conclusion of Thompson in 2002, the FDA issued yet another
CPG regarding compounding practices that suggested a continued enforcement
reliance on the factors enumerated in Section 503A, as previously passed
through the FDAMA, just without enforcement of the marketing prohibition. 121
The 2002 CPG therefore narrowed the FDA’s focus to specifically those
“[p]harmacies engaged in activities analogous to manufacturing and
distributing drugs . . . ,” and imposed reliance on the states to take care of “less
significant violations of [503A].” 122 Yet again, the CPG gave compounders
another non-exhaustive list of nine factors that would be considered before the
FDA would elect to take action. 123 Some of these nine factors addressed
concerns such as: the quantities of compounds made prior to receiving
prescriptions or in commercial scales, whether compounds included drugs
removed from market, using substances not confirmed from an FDA registered
facility or meeting compendia requirements, making copies of drugs
commercial available, and failing to conform with state law regarding the
practice of pharmacy. 124
However, all of these clarifications and rules only muddled the thinking as
to how, or if, the FDA would enforce compounding standards in the future
even though the FDCA gave the FDA authority to do so. Part of the problem
was to be addressed by the FDA’s reliance on the states, however, “piratemanufacturers” still eluded some state officials and again showed that it was
necessary for the FDA to act in some occasions.
B.

State Regulation

Every state has a “pharmacy practice act” that creates authority for a SBOP
to oversee the practice of pharmacy within their state. 125 SBOPs generally
consist of around ten members—often pharmacists from various backgrounds
plus or minus an at large public member, all of whom act as directors for the

119. Boodoo, supra note 34, at 239; see also Mukasey, 536 F.3d at 409.
120. 21 C.F.R. § 310.3(h)(1)-(2) (2015).
121. FOOD & DRUG ADMIN., COMPLIANCE POLICY GUIDANCE FOR FDA STAFF AND
INDUSTRY 3 (2002) [hereinafter 2002 CPG].
122. Id. at 3.
123. Id. at 3-4.
124. Id.
125. NAT’L ASS’N OF BDS. OF PHARMACY, MODEL STATE PHARMACY ACT AND MODEL
RULES OF THE NATIONAL ASSOCIATION OF BOARDS OF PHARMACY § 201 (2012), [MODEL
STATE PHARMACY ACT hereinafter Model State Pharmacy Act] www.nabp.net/publications/
model-act; see, e.g., MO. CODE REGS. tit. 20 § 2220-1.010 (2014).
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agency’s resources and people. 126 Traditionally, SBOPs are responsible for
overseeing the licensing of pharmacists, technicians (if applicable), pharmacy
interns, pharmacies, wholesalers, and manufacturers of drugs within their
state. 127 They are also responsible for investigating complaints or suspicious
activities of pharmacy professionals or facilities and employ inspectors and
other support staff to fulfill these duties. 128
SBOPs are usually focused on policing the professionals and facilities
within their jurisdiction since the FDA has more authority over the goods a
pharmacy sells, but less as to how they are sold and dispensed by a
pharmacist. 129 The compounding of medications, which is expressly described
in the state’s pharmacy practice act also grants the state boards authority to
regulate compounders and prescriptions being dispensed within their
borders. 130 Moreover, it understood that the FDA relies on state boards “to
have primary responsibility for the day-to-day oversight of state-licensed
pharmacies that compound drugs in accordance with [traditional practices].” 131
However, some SBOPs may not be as equipped as others to handle the
intricacies of numerous compounding inspections. Budgets for SBOPs can
vary greatly, and employment of inspectors and timely action depends on
legislative allocations and the SBOP’s ability to respond to complaints. 132
Because of such limited resources, states are generally slow to identify, act on,
or follow up with bad actors in the profession as evidenced by the lack of
follow up in the case of NECC. 133
SBOPs are not entirely without guidance when it comes to compounding
and inspection issues. The National Association of Boards of Pharmacy

126. CONGRESSMAN MARKEY ET AL., STATE OF DISARRAY: HOW STATES’ INABILITY TO
OVERSEE COMPOUNDING PHARMACIES PUTS PUBLIC HEALTH AT RISK 30 (2013), www.mar
key.senate.gov/imo/media/doc/State%20Of%20Disarray%20Compounding%20Report.pdf.
127. MODEL STATE PHARMACY ACT, supra note 125, at § 213(a)(1); see also Missouri
Pharmacy Practice Act, Mo. Rev. Stat. § 338 (2015) (using Missouri as an example of a state
pharmacy practice act).
128. MODEL STATE PHARMACY ACT, supra note 125, at § 213(a)(12); Mo. Rev. Stat. § 338
(2015).
129. See generally Thompson v. W. States Med. Ctr., 535 U.S. 357, 360 (2002) (inferring that
historically, FDA action has largely been limited to pirate manufacturers of compounded
products).
130. See e.g., MODEL STATE PHARMACY ACT, supra note 125, at § 213(a)(9).
131. Compounding and the FDA, supra note 14.
132. OFFICE OF EVALUATION & INSPECTIONS, STATE DISCIPLINE OF PHARMACISTS 3 (1990).
133. Id.; Toni Clark & Sharon Begley, Insight: Red Flags Ignored For Years at Firm In
Meningitis Crisis, REUTERS (Oct. 26, 2012), www.reuters.com/article/us-usa-health-meningitisne cc-idUSBRE89P12N20121026. The Massachusetts Board of Pharmacy issued warning letters,
as did the FDA in 2006, however it failed over the next three years to adequately follow up with
NECC to ensure the facility’s compliance with the pharmacy practice statutes and federal
guidelines. Id.
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(NABP) does its best to help minimize these variances among states by
developing and updating a “Model State Pharmacy Act” and publishing
newsletters helping SBOPs and pharmacists stay updated and focused on
potential problem areas in regulation. 134
Yet with the model act and newsletters, there is still a patchwork of
regulatory inconsistencies and adoption of the model act can vary from state to
state. States that do adopt changes to their pharmacy practice acts may do so at
varying paces, thus lagging legislatures may cause further variance of
pharmacy regulation from state to state. Examples of these variances exist in
classification systems of pharmacies. Some states, like Missouri, require any
pharmacy utilizing bulk ingredients to compound a medication to be registered
and possess either a Class D (non-sterile product) or Class H (sterile product)
Missouri pharmacy license. 135 Other states, like Pennsylvania, have no
classification or licensing system required to compound medications, sterile, or
non-sterile compounds under their regulations, 136 while other states, like
Florida and Ohio, have placed disclosure requirements on facilities in the past
years. 137 Furthermore, with the ease of shipping prescription medications,
some states have tried to require a pharmacy to obtain a license to ship
prescription products to patients in their state. 138 This requirement may allow
for SBOPs to potentially track where prescription medications are coming
from in their state, however, there is no reliable way for them to enforce this
policy, especially with pharmacies that reside many states away, right on
borders, or those just ignoring state laws.
States and the FDA have led two very different paths in regulating and
defining acceptable compounding practices for the pharmacy profession.
Inconsistent standards, challenges of enforcement authority, and bad actors
such as NECC reaffirm the need for compounders and enforcement agencies to
have clear guidelines on compounding from legislators. However, past
attempts to clarify these similar issues have hit many historical bumps, so the
question remains as to just how effective could new legislation be in regulating
compounding and ensuring patient safety?

134. See MODEL STATE PHARMACY ACT, supra note 125.
135. MO. CODE REGS. ANN. tit. 20 § 2220-2.020 (2013).
136. See 27 PA. CODE § 27.18 (2012).
137. Sterile Compounding Permit, FLA. BOARD PHARMACY (2016), http://floridaspharmacy.
gov/licensing/sterile-compounding-permit/; Compounding in Ohio, ST. OHIO BOARD PHARMACY,
https://www.pharmacy.ohio.gov/Documents/Pubs/Special/Compounding/Compounding%20in%
20Ohio.pdf (last updated Oct. 28, 2015).
138. KY. REV. STAT. ANN. § 315.0351 (West 2007); see also OHIO REV. CODE ANN. §
4279.54 (West 2014).
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V. THE “NEW REGULATION” OF COMPOUNDING – THE DRUG QUALITY AND
SECURITY ACT
The failure of the MSBP and the FDA in preventing the NECC tragedy
demonstrated that agencies and legislatures needed to refocus regulatory
efforts of pharmaceutical compounding after almost ten years in the shadows.
Mass publicity of the unsanitary conditions, lack of patient prescriptions, and
mass marketing scheme, elevated the epidemic to a top concern of law makers
and labeled it as a public health disaster. 139 However, even in spite of the
NECC tragedy, many immediate attempts to regulate compounding by stricter
laws have stalled or ultimately failed passing in state and federal
legislatures. 140 As a result, Congress attempted to once-and-for-all clarify FDA
oversight of compounding pharmacies and more importantly to ensure that the
FDA could take swift action to combat compounds that were not made in
accordance with relevant standards of practice.
A.

Federal Regulation—Outsourcing Facilities

While patients continued to present with symptoms and suffer side effects
of meningitis as a result of the NECC steroids, 141 U.S. Congressman Fred
Upton of Michigan, whose district had three of the nineteen NECC related
deaths in Michigan, 142 introduced the DQSA to the U.S. House of
Representatives on September 27, 2013. 143 The DQSA set forth new
clarifications and additional regulations of compounding. 144 The DQSA passed
the House on September 28, 2013, and then quickly passed the Senate without
amendment on November 18, 2013. 145 President Obama signed the DQSA on
November 27, 2013, as Public Law 113-54. 146
The DQSA amended the FDCA by “protect[ing] traditional pharmacies
and clarify[ing] laws related to human drug compounding.” 147 The DQSA

139. Press Release, House Energy & Commerce Comm., Upton Introduces H.R. 3204, the
Drug Quality and Security Act, in Response to Deadly Meningitis Outbreak (Sept. 27, 2013),
http://upton.house.gov/news/documentsingle.aspx?DocumentID=351595.
140. See generally 2014 State Compounding Legislative Tracker, INT’L ASS’N
COMPOUNDING PHARMACISTS, http://c.ymcdn.com/sites/www.iacprx.org/resource/resmgr/Com
pounders_Stateside/IACP_Weekly_Summary_of_State.pdf?hhSearchTerms=%222014+and+state
+and+compounding+and+legislation+and+tracker%2 (last updated Dec. 12, 2014) (showing the
progress of several compounding safety related bills, including those failing to gain approval and
those stuck in committee).
141. Press Release, House Energy & Commerce Comm., supra note 139.
142. Id.
143. See Drug Quality and Security Act, supra note 26.
144. See id.
145. Id.
146. Id.
147. Press Release, House Energy & Commerce Comm., supra note 139.
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consists of Title I relating to drug compounding and Title II relating to the
Drug Supply Chain Security. 148 Title I clarifies Section 503A, removes the
marketing prohibition from the FDAMA that was controversial, and thus has
likely provided a clear and actionable definition of traditional compounding
and a separate category for those to be labeled as “outsourcing facilities.” 149 A
new section, Section 503B, relating to outsourcing facilities, was inserted after
Section 503A and shifted the existing Section 503B of the FDCA to Section
503C. 150 Moreover, the DQSA requires the FDA to collect reports from
SBOPs regarding actions against compounders through enhanced
communication methods. 151 The DQSA took effect January 1, 2015, however,
there are still some agency rules needing further action before full enforcement
may occur. 152
The amended Section 503B allows pharmacies to register as “outsourcing
facilities” via a voluntary registration process that is subjected to enhanced
regulation by the FDA. 153 However, the DQSA’s definition of outsourcing
facilities is inadequate to protect the public because it excludes non-sterile
compounds, does not require a facility to have a pharmacy license, and
removes the single patient prescription requirement. 154 Section 503B
specifically defines “outsourcing facilities” as:
a facility at one geographic location or address that . . . is engaged in the
compounding of sterile drugs [emphasis added] . . . [that] has elected to
register . . . complies with all of the requirements of [the] section . . .
[furthermore] [a]n outsourcing facility is not required to be a licensed
pharmacy . . . [and] may or may not obtain prescriptions for identified
155
individual patients.

However, the limitation to only sterile drugs under the DQSA misses an
opportunity for enhanced FDA regulation of compounding and is suggestive
that future FDA enforcement should not be concerned with non-sterile

148. Drug Quality and Security Act, supra note 26, at tits. I, II. Title II introduces additional
provisions to make drugs easier to trace (from manufacturer to patient) throughout the U.S.
supply chain. Id. However, it will not be discussed in this paper, and, as such, the term DQSA
will relate to Title I only.
149. Id. § 102(a).
150. Id.
151. Id. § 105(a)(1).
152. See id. § 503B(a)(2)(A)(i) (noting that the Secretary is to establish a list of bulk drug
substances).
153. Drug Quality and Security Act, supra note 26, at § 503B(a)(1).
154. Id. § 503B(d)(4).
155. Id. § 503B(d)(4)-(5).
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compounding—even on a large scale. 156 However, even with such focus,
Section 503B’s registration is completely voluntary and only applicable to
those “outsourcing facilities” producing sterile drugs that may be compounded
with or without a patient name. 157 Section 503B also departs from the idea that
compounders, who are generally not regarded or registered as manufacturers,
may now produce sterile compounds as “mini manufacturers” for hospitals,
ambulatory care centers, physician office use, etc. without a prescription. 158 As
such, the DQSA gives credence to historically-labeled “pirate manufacturers”
in compounding, so long as they register as an outsourcing facility and that
these “new drugs” being compounded or manufactured without a patient
specific prescription, would not be required to go through the approval process
laid out by the 1962 Amendments. 159
Instead, the registration process under the amended Section 503B provides
an incentive to outsourcing facilities compounding these non-patient specific,
sterile medications. 160 Section 503B exempts registered outsourcing facilities
from violations arising under FDCA Section 502(f)(1) (misbranding), 161
Section 505 (new drugs), 162 and Section 582 (substances generally recognized
as safe), 163 if the compounds made in these facilities are done so by or under
the direct supervision 164 of a licensed pharmacist in a registered facility that
meets the other conditions of the section. 165 Therefore, registration as an
outsourcing facility and successful inspection by the FDA will be a “safe
harbor” from violations of the aforementioned sections of the FDCA. 166
The extent of how many entities producing sterile compounds and
volunteering to undergo this registration is still unknown; however, it is not
very likely to be widespread. There is a great amount of work and expense
required prior to inspection by the FDA, especially in implementing CGMPs

156. Id. Indicative of this focus on sterile drugs, the Act even further defines a “sterile drug”
as “a drug that is intended for parenteral administration, an ophthalmic or oral inhalation drug in
aqueous format, or a drug that is required to be sterile under Federal or State law.” Id.
157. Id. at § 503B(b).
158. See Drug Quality and Security Act, supra note 26, at § 503B(b).
159. 1962 Amendments, supra note 89, at § 102(d).
160. See Drug Quality and Security Act, supra note 26, at § 503B(a)(1).
161. See id.
162. See id.
163. See id.
164. See id. While the FDA does not define direct supervision, it is generally understood by
the pharmacy profession as requiring “a pharmacist [to] be physically present in the pharmacy, or
in the area where the practice of pharmacy is occurring, and provide personal review and
approval of all professional activities.” OHIO ADMIN. CODE § 4729-5-01 (2014). Terms like
“area” however remain vague and are open to interpretation by state inspectors. Id. (failing to
define the term “area,” thus opening such terms up for interpretation).
165. See generally Drug Quality and Security Act, supra note 26, at § 503B(a)(1).
166. See id.
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which are more stringent than USP standards. Furthermore, each facility has to
allow for the flexibility to adapt to changing lists still yet to be promulgated by
the Secretary of Health and Human Services (HHS) 167 and that have been
repeatedly pushed back. 168 Moreover, several requirements that all outsourcing
facilities must prove and adhere to throughout their initial and continued
registration are laid out by the DQSA’s Section 503B. 169 Missing any one part
of the requirements, as written, will not afford the outsourcing facility the
exemption from the aforementioned parts of the FDCA. To qualify for
registration and thus the exemption, the following must be met: 170
1. The outsourcing facility is in compliance with CGMPs.

171

2. A drug compounded can not contain bulk drug substances unless each
substance is identified on a list of established substances approved, or in
172
173
The bulk substance then must
shortage at the time, by the Secretary.
be accompanied by a valid certificate of analysis, be manufactured by an
174
and if applicable must
establishment registered under Section 510(i),
175
comply with USP-NF or other recognized compendium monograph.
3. All ingredients other than bulk substances used must comply with the USP,
176
NF, or other compendium recognized by the secretary.
4. The drug substance or other ingredient must not be withdrawn due to safety
177
or efficacy concerns.
5. The finished drug is not “essentially a copy” of an approved drug.

178

167. The Secretary of HHS is undergoing the formal rule making process of establishing such
a list from each outside stakeholder submitting comments. See List of Bulk Drug Substances that
May Be Used in Pharmacy Compounding; Bulk Drug Substances that May Be Used to
Compound Drug Products in Accordance with Section 503A of the Federal Food, Drug, and
Cosmetic Act, 78 Fed. Reg. 72,841, 72,841-42 (Dec. 4, 2013).
168. See FOOD & DRUG ADMIN., PHARMACY COMPOUNDING OF HUMAN DRUG PRODUCTS
UNDER SECTION 503A OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT: GUIDANCE 5 (2015)
[hereinafter 503A GUIDANCE].
169. Drug Quality and Security Act, supra note 26, at §§ 503B(a), 503B(b).
170. Id. §§ 582(a)(3)(ii), 582(a)(3)(iii).
171. Id. § 503B(a)(1). See generally 21 C.F.R. § 211 (2014). Current Good Manufacturing
Practices are lists of extensive procedures designed to protect consumers from deficiencies in
manufacturing processes. Id.
172. Drug Quality and Security Act, supra note 26, at § 503B(a)(2)(A).
173. Id.
174. 21 U.S.C. § 351(i) (2012).
175. Id. § 351(a).
176. Id. § 351(c).
177. Id. § 351(d)-(e).
178. Drug Quality and Security Act, supra note 26, at § 503B(d)(2). “Essentially a copy” is
defined by section 503B as “(A) a drug that is identical or nearly identical to an approved drug, or
a marketed drug not subject to section 503(b) . . . ,” not on a list of drug shortages “at the time of
compounding, distribution, and dispensing; or (B) a drug, a component of which is a bulk drug

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

2016]

A FALSE SENSE OF SAFETY

353

6. The finished drug is not demonstrably difficult for compounding—as
179
determined by a list to be published by the secretary.
7. The facility has an appropriate risk evaluation control system in place if the
drug is compounded utilizing an ingredient indicated by an FDA Risk
180
Evaluation and Mitigation Strategies (REMS) program.
8. The compounded drug must not be available for “wholesale” or sale by an
181
entity other than the outsourcing facility.
9. The drug is labeled appropriately.

182

Other requirements include paying of outsourcing facility registration
fees, 183 and ensuring that the facility is in compliance with Section 503B(b),
which sets the registration and reporting standards of drugs at an outsourcing
facility. 184 The fees mentioned by the DQSA appear in Section 744K of the
FDCA, on which the FDA released guidance at the beginning of the 2015
fiscal year. 185 The annual registration fee is an up-front payment of $15,000
(adjusted for inflation) 186 that includes registration and initial inspection. 187
However, on the likely chance that the outsourcing facility does not pass initial
inspection and after FDA follow-up to verify that the initial deficiencies are
corrected, an outsourcing facility is subject to a re-inspection fee of another
$15,000 for each subsequent inspection deemed necessary before the facility is

substance that is a component of an approved drug or a marketed drug that is not subject to
503(b) and not subject to approval in an application submitted under section 505, unless there is a
change that produces for an individual patient a clinical difference, as determined by the
prescribing practitioner . . . .” Id.
179. Id. § 503B(a)(6)(A). The FDA has requested submissions. See List of Bulk Drug
Substances that May Be Used in Pharmacy Compounding; Bulk Drug Substances that May Be
Used to Compound Drug Products in Accordance with Section 503A of the Federal Food, Drug,
and Cosmetic Act, 78 Fed. Reg. 72,841, 72,841-42 (Dec. 4, 2013).
180. Drug Quality and Security Act, supra note 26, at § 503B(a)(7).
181. Id. An outsourcing facility may not contract with another pharmacy to become a
wholesaler of sterile medications to patients or physician use. Id.
182. Id. § 503B(a)(10).
183. FOOD & DRUG ADMIN., FEES FOR HUMAN DRUG COMPOUNDING OUTSOURCING
FACILITIES UNDER SECTIONS 503B AND 744K OF THE FD&C ACT: GUIDANCE FOR INDUSTRY 2
(2014) [hereinafter FEES 744K].
184. Drug Quality and Security Act, supra note 26, at § 503B(a)(10)(b).
185. FEES 744K, supra note 183, at 1.
186. Id. at 2. Amount will be $15,000 multiplied by the inflation adjustment factor
compounded each year. Id. The inflation adjustment factor will be set as one plus the average
annual percentage in change of cost per full-time equivalent (FTE) position at FDA for three of
the preceding four fiscal years, multiplied by compensation and benefits costs, plus the average
percentage change in the consumer price index (CPI) multiplied by the proportion of all costs
associated with the cost of an average FTE position at the FDA. Id. at 4-5.
187. Id.
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in compliance with CGMPs. 188 For example, if a facility fails inspection the
first time, and then does not appropriately remedy its deficiencies, a $15,000
fee for a third inspection may be assessed.
Smaller businesses may have their fee reduced to $5,000 for registration
and an initial inspection, however, businesses are only eligible upon advanced
submission of a written request and certification stating that the facility (1)
qualifies for such reduction, and (2) the facility’s sales are less than one
million dollars annually. 189 This small business reduction also only applies to
the initial/annual registration and not the re-inspection fee. 190 Therefore, if a
re-inspection is assessed against the small business, that business will be
responsible for paying the entire fee of $15,000 for each re-inspection. 191
Currently, fifty nine facilities have sought registration as an outsourcing
facility, 192 however, this number fluctuates and has been as high as seventynine at times. 193 While some inspections (twelve) are still pending, the FDA
issued a Form 483 to every single one of the facilities it has inspected to
date. 194 This is meaningful because a Form 483 puts an outsourcing facility on
notice that inspectors have found objectionable conditions, potentially
including deficiencies in CGMPs, which “may constitute a violation of the
[FDCA] . . . and [other] related acts.” 195 Because all forty-seven of the
inspected firms were issued Form 483s, the DQSA would not afford them full
protection granted through registration because that facility was not in full
compliance with CGMPs and the statute. 196 Therefore, until the FDA has reinspected these facilities and found them in full compliance, these companies
are still open to liability under the FDCA. 197 To date, though, the extent of
FDA action against an outsourcing facility under the new Section 503B has
been limited to a warning letter or Form 483. 198

188. Id. at 5. Re-inspection is assessed when the FDA has to visit the outsourcing facility
beyond the initial follow up to a noted deficiency upon initial inspection. Id.
189. Id. at 6. Sales of one million dollars do not have to be related to compounding activities,
rather they encompass all sales associated with the business and not limited to drugs. Id.
190. FEES 744K, supra note 183, at 6.
191. Id.
192. Registered Outsourcing Facilities, FOOD & DRUG ADMIN. (Apr. 17, 2016),
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/
ucm378645.htm#6.
193. Id. Some registrants may have pulled their registration after unsuccessful attempts to
pass inspection. Id.
194. Id.
195. FDA Form 483 Frequently Asked Questions, FOOD & DRUG ADMIN., http://www.fda.
gov/ICECI/Inspections/ucm256377.htm (last visited Feb. 17, 2015).
196. Drug Quality and Security Act, supra note 26, at § 503B(a); Registered Outsourcing
Facilities, supra note 192.
197. Drug Quality and Security Act, supra note 26, at § 503B(a).
198. See Registered Outsourcing Facilities, supra note 192.
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Additionally, the DQSA calls for enhanced communication between
SBOPs and the FDA. 199 The DQSA now requires the FDA to collect reports
from SBOPs regarding any state actions or agency concerns individual states
have about a compounding pharmacy acting outside of Section 503A. 200
However, this requirement has little regulatory capability and serves mainly for
documentation purposes if the FDA were to take action against individual
pharmacies in a certain state.
The DQSA undoubtedly addresses large-scale sterile compounders and
suggests enhanced record keeping requirements on a state level, however the
opportunities to address larger issues that could directly affect the efficacy of
compounding regulation seem to have been passed on. While the DQSA does
not miss all opportunities to effect change, it does firmly and finally establish a
true definition of compounding for the FDA and state agencies, however,
enforcement of the definition will likely require more than just the words
included in the Act.
VI. REGULATORY CONSEQUENCES AND OVERSIGHTS
Although the DQSA provides a much-needed system of registration for
large-scale compounders, it leaves potentially dangerous regulatory oversights
that could have provided a higher degree of public safety in compounded
medications. 201 These gaps arise greatly by making the process voluntary and
specific to sterile compounds, while missing the larger problem of identifying
compounding pharmacies and facilities. Furthermore, the increased pressure
and enhanced duties of reporting imposed on SBOPs may strain already
overworked SBOPs and further exhaust tight budgets.
A.

DQSA Does Not Identify Sterile Compounders Nationwide

According to a report to the House Energy Committee written months
before passing the DQSA, SBOPs and compounding are in a “[s]tate of
[d]isarray.” 202 As of April 15, 2013, only two states routinely tracked the
number of compounding pharmacies in their state, and, moreover, only thirteen
states even knew what pharmacies were compounding sterile products. 203
Fixing the problems in compounding regulation requires knowledge of just
how big of a problem there may be. Legislators may have failed to realize the
ease of traditional retail pharmacies expanding service lines to include
compounding, or even the number of new compounding pharmacies that have
been opened. In a field like pharmacy, patients could suffer from the naivety of
199.
200.
201.
202.
203.

Drug Quality and Security Act, supra note 26, at § 105(a).
Id.
See generally CONGRESSMAN MARKEY ET AL., supra note 126.
Id.
Id. at 3, 17.
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these emerging practices. But the DQSA does very little to aid any agency in
identifying these emerging or existing compounding pharmacies for regulators.
If we were to examine the compounders in the U.S., two natural types would
emerge: those providing large quantities (mainly to hospitals, doctors’ offices,
and infusion centers) and those compounding for the general public need based
on a patient specific basis. While volume of sterile compounds dispensed can
vary in each category, a categorical difference arises because most “closeddoor” 204 compounders provide products for wholesale purposes—much like
the practices NECC was engaged in. But having no mandatory identification of
compounding activities for these two types of pharmacies presents different
difficulties to patient safety, and without mandatory identification, neither state
boards nor the FDA can always accurately assess and inspect the facilities to
uncover potential risks to public health.
Many large-scale compounding facilities that would register with the FDA
today gear sales towards institutional clients like doctors’ offices, hospitals,
and ambulatory care centers. This trend holds true when examining the types
of facilities that have voluntarily registered with the FDA to date, but the
question arises as to why only fifty-nine facilities have registered? 205 Other
facilities like those registered should be jumping to be labeled as an
outsourcing facilities under the DQSA to take advantage of the FDCA
exemptions, but many are likely not. Logic suggests that low registration could
be due to reasons such as the past history of the FDA and SBOPs minimal
action against these types of facilities, the facilities could not meet the CGMPs
necessary (as demonstrated by the numerous issuances of Form 483), 206 or
even because agencies were ill equipped to identify these actors, 207 which
would allow the facilities to take their chances and slip under the regulatory
radar.
Thus, creating a voluntary registration, regardless of the safe harbor, has
been realistically inefficient in identifying and encouraging those engaging in
mass-compounding to register as an outsourcing facility. Unless a facility has a
lot to lose, or they are close already to complying with the heightened CGMP

204. Eileen Beal, Closed-door Pharmacy Provides Patients With Worry-free Process,
CRAIN’S CLEVELAND BUS., Oct. 5, 2012. “Closed door” is a term used to indicate the pharmacy
generally has no “walk-in” or retail-public (where anyone can be a customer) type of business
model. Id. Instead sales are usually done through liaisons of the pharmacy or facility direct to
physicians, hospitals, or in some cases patients, etc. Id.
205. Registered Outsourcing Facilities, supra note 192. A breakdown of the pharmacies
included on the list as of January 30, 2015 include only four pharmacies with public retail
prescriptions. Id.
206. Id.
207. Massachusetts had no idea of the sterile compounding pharmacies in their state until
after NECC when they received thirty-nine self-disclosures for sterile compounding pharmacies.
CONGRESSMAN MARKEY ET AL., supra note 126, at 11.
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standards and passing FDA inspection, voluntary registration will only
minimally incentivize awareness of these compounding facilities and the
conditions in which they produce their products.
Apart from the outsourcing type facilities, pharmacies that provide sterile
compounds mainly for the general public are also not likely to register as an
outsourcing facility even if they decide they will “outsource” some amount of
prescriptions each year to a doctor’s office or hospital. General public retail
pharmacies provide patients with sterile compounds like preservative free
vitamin injections, erectile dysfunction injections, 208 or fortified eye drops, 209
which all need to meet sterility requirements under the USP. 210 These
compounds are made by the local independent or possibly chain drug store
pharmacies, some of which may compound hundreds of sterile products a
month or others just a few. However, strict adherence to USP standards may
vary across pharmacies, so therefore trying to comply with heightened CGMPs
would not be an incentive to register. Moreover, some compounding
pharmacies lack the necessary equipment to even perform these sterile
manipulations safely. Therefore, while Section 503B may be alluring to some,
many general public pharmacies will likely pass on registration.
Another deterrent, besides a detailed FDA inspection, that general-public
pharmacies will face to registration is the annual cost of registration under
Section 503B. Most pharmacy businesses will easily exceed the million-dollar
sales ceiling provision in Section 503B that would qualify the business for a
reduced-fee inspection and registration fee. The average pharmacy has about
three million dollars in sales a year, 211 and while some may argue that the
pharmacy could surely afford the higher fee, the margin from three million
dollars in sales may not even equate to much more than breaking even in the
end. 212 Most pharmacies used by the general-public receive marginal

208. See Sterile Preparations/Injectibles, BUDERER DRUG CO., https://www.budererdrug.
com/clinicians-corner/sterile-preparationsinjectables/ (last visited Feb. 18, 2016). Common
examples of indications for which an injection would be used include: erectile dysfunction,
preservative free vitamin injections, and hormone injections. Id.
209. Steroid and Antibiotic Eye Drops, MEDICINENET.COM (Apr. 14, 2015), http://www.medi
cinenet.com/steroid_and_antibiotic_eye_drops/article.htm. Fortified eye drops are often
commercial antibiotic or steroid eye drops modified to increase concentrations of active drugs for
serious eye infections or inflammation. Id.
210. See generally <71> STERILITY TESTS, U.S. PHARMACOPEIAL CONVENTION, supra note
71.
211. Nat’l Pharmacists Ass’n, 2013 NCPA Digest: Community Pharmacy in the Digital Age,
NCPA DIGEST, 2013, at 6, http://www.ncpanet.org/docs/default-source/default-document-library/
2013-ncpa-digest-sponsored-by-cardinal-health.pdf.
212. Id. The average independent pharmacy has typically had three million dollars in sales in
each of the last ten years at the time the DQSA was passed. See id. Therefore, the small business
reduction would not apply, as the language indicates total sales, and thus not specific to
prescriptions or even compounded medication sales only. See id.
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reimbursements on commercially-produced (already FDA approved)
medications, 213 have high overhead costs, and a low profit margin. 214
Therefore, costs associated with CGMPs and the general expense of operating
a pharmacy may prohibit or discourage owners from registration of their
facility under Section 503B. Adding compounding, without increasing annual
fees, therefore allows these pharmacies to supplement the money they are
likely losing from low commercial medication reimbursements, as often
compounds are billed for cash prices and without insurance. 215
Therefore, because of the low ceiling for a small business exemption that is
easily exceeded, the high costs to voluntary registration, and an overall lack of
uniform requirements for identification imposed by many states, most of the
general-public pharmacies engaging in sterile compounding will simply not
register or will try to “fit” within the 503A exemption. Because of the
aforementioned reasons that DQSA provided no mandatory process to identify
sterile compounders or compounders in general, it may do little to ensure that
stricter standards of compounding (USP or CGMPs) will be followed
nationwide.
B.

Failure in Not Including Non-Sterile Compounds

The DQSA’s silence regarding non-sterile compounds may be a critical
oversight that allows for other compounding tragedy. Non-sterile compounds
may be just as dangerous as sterile compounds when wrongfully prepared. 216
Non-sterile compounds containing ingredients with narrow therapeutic
indices, 217 dangerous properties, short stabilities, and those with complex pH
requirements, 218 are commonly made across the country and often include

213. See id. at 7.
214. See id.
215. See generally Lisa Causey, Nuts and Bolts of Pharmacy Reimbursement: Why It Should
Matter To You, U. HOUS. HEALTH L. PERSPECTIVES (2009), http://www.law.uh.edu/healthlaw/
perspectives/2009/(LC)%20Pharmacy.pdf.
216. See Boodoo, supra note 34, at 227.
217. 21 C.F.R. § 320.33(c) (2015). A narrow therapeutic index drug is a drug in which “there
is less than a 2-fold difference in median lethal dose (LD50) and median effective dose (ED50)
values, or have less than a 2-fold difference in the minimum toxic concentrations and the
minimum effective concentrations in the blood, and safe and effective use of the drug products
requires careful dosage titration and patient monitoring.” Id.
218. See Tommy Andersson et al., Pharmacokinetics of Orally Administered Omeprazole in
Children, 95 AM. J. GASTROENTEROLOGY 3101, 3101 (2000). Omeprazole (brand: Prilosec™) a
common gastric reflux medication for infants, requires a specific pH not less than 7.8 to be
effective at neutralizing acid in the stomach, or drug degradation can occur before effect is
realized. LAWRENCE A. TRISSEL, TRISSEL’S™ STABILITY OF COMPOUNDED FORMULATIONS
359-363 (5th ed. 2012). Omeprazole, however, is not commercially manufactured in liquid form
and compounders nationwide make this suspension daily. Id.
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hormone, pain, and pediatric medications. 219 For instance, imagine if an
individual ingested a capsule containing nearly three times more than the
prescribed and labeled amount (i.e., 300% potency) of thyroid medication, 220
he or she could experience cardiac arrest or other side effects from overdosing.
Similarly, if a patient received an antibiotic liquid of vancomycin 221 that was
not stored properly or sat on the shelf for too long, the antibiotic may be
ineffective at treating serious bacterial diseases that result in life-threatening
conditions. 222 These are just a few of the mistakes posing serious risks to
patient safety that could occur in the process of making non-sterile compounds.
Not including non-sterile compounders that act as “outsourcing type
facilities” in the DQSA’s registration may cause these facilities to continue
their current outsourcing practices without stricter scrutiny. Although the
DQSA reiterates a prohibition on outsourcing (or wholesaling) to physicians’
offices, some SBOPs still permit the practice on a limited basis thus creating a
rift between state and federal law. 223 Therefore, compounders are continuing to
roll the dice in their practice of wholesaling non-sterile “office use only”
compounds, potentially without enhanced safeguards required. 224 Physicians
only further incentivize this behavior because they are in constant need of
ointments, creams, and other compounded medications, which can be

219. <795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS, U.S.
PHARMACOPEIAL CONVENTION, supra note 17, at 1, 4-5.
220. Dosages of thyroid medications are often measured in micrograms and titrated slowly
due to side effects associated with overdosing a patient. See generally Hypothyroidism In-Depth
Report, N.Y. TIMES, http://www.nytimes.com/health/guides/disease/hypothyroidism/print.html
(last visited Jan. 23, 2016). Millions of patients in the U.S. take a thyroid medication known as
Synthroid, however, some patients need higher quantities of the active drug, or are allergic to
fillers in the commercially manufactured tablets which often contain dye. Id.
221. See Vancomycin, DRUGS.COM, http://www.drugs.com/vancomycin.html (last revised
Mar. 27, 2014). Compounded vancomycin suspensions are often used for the treatment of a
bacteria, Clostridium difficile, which causes life-threatening inflammation of the colon. Id.
Vancomycin is available as an FDA approved drug in capsule form, but due to the high costs of
capsules, some prescription insurance companies do not cover the medication, or require the
patient to get a compounded form of the drug. Id.
222. Vancomycin Hydrochloride, PHARMACOPEIA ONLINE (2013), http://www.uspbpep.com/
usp31/v31261/usp31nf26s1_m87760.asp (last visited Jan. 22, 2016); see also <1> INJECTIONS,
U.S. PHARMACOPEIAL CONVENTION, USP38-NF33, 65 (U.S. Pharmacopeial Convention 2015)
(describing standards for storage of injection medications).
223. E.g., ST. OHIO BOARD PHARMACY, supra note 137 (showing that a pharmacist is
allowed to compound a commercially unavailable medication).
224. See OHIO ADMIN. CODE § 4729-16-07 (2016); ST. OHIO BOARD PHARMACY, supra note
137. Office-use only compounds are those purchased by the physician and administered directly
to a patient in-office. See generally OHIO ADMIN. CODE § 4729-16-07. In practice, the compound
does not leave the office nor is it given to the patient for continued treatment. Id.
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customized to their preferences, to perform tests and treatments in office and at
a premium. 225
Therefore, from a public welfare and pharmacy practitioner’s perspective,
leaving out non-sterile compounding does not necessarily ensure that
compounding is “safer” for all. The DQSA thus fails in part because it should
have been broad enough to allow a facility producing and dispensing sterile,
non-sterile, or both, types of compounds without a patient specific prescription
the ability to register. Including all forms of compounds would have then
shifted the emphasis of the Act and its exceptions to focus on having a
prescription, regardless of the type of compound and thereby minimizing the
potential for another large-scale batched tragedy.
C. Problem with Reliance on State Boards While Providing No Additional
Help
The DQSA may be viewed as an attempt to strengthen state regulation of
compounding pharmacy, but it provides little means to accomplish this task.
The mere creation of an enhanced method to communicate actions against
compounders between SBOPs and the FDA 226 is simply not enough. The
DQSA recognizes and supports the FDA’s reliance that the SBOPs will have
primary responsibility in enforcement and day-to-day oversight of pharmacies
that engage in compounding, 227 but provides no additional resources or fees
from outsourcing facilities to do so. 228 The FDA has also reiterated this same
position after passage of the DQSA in its “expect[ation that] state boards of
pharmacy . . . continue their oversight and regulation of the practice of
pharmacy, including pharmacy compounding” under Section 503A. 229 Yet in
its statement, the FDA mentions no provision of additional resources to aid
SBOPs. 230 Furthermore, because the marketing prohibition of Section 503A
(created by the FDAMA) was removed by the DQSA, Section 503A is
therefore applicable in all jurisdictions. 231 With Section 503A in full effect,
state actions should increase, although, this assumes that SBOPs have the
money to initially investigate and bring actions against different facilities.
Because the burden still clearly remains on the states to address compounding
enforcement, but they are provided no further help from the FDA or Congress

225. See T.R. GOLDMAN, HEALTH AFF., REGULATING COMPOUND PHARMACIES 1-2 (2014),
http://healthaffairs.org/healthpolicybriefs/brief_pdfs/healthpolicybrief_114.pdf.
226. Drug Quality and Security Act, supra note 26, at § 105.
227. See Compounding and the FDA, supra note 14.
228. See generally Drug Quality and Security Act, supra note 26, at §§ 105, 744K(a).
229. 503A GUIDANCE, supra note 168, at 3.
230. See generally id.
231. Drug Quality and Security Act, supra note 26, at § 105.
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via additional resources, SBOPs may further struggle to keep the public safe
from bad and negligent actors in compounding. 232
VII. POSSIBLE SOLUTIONS TO REGULATORY GAPS
Even with the shortfalls of compounding regulation, several solutions are
available to help identify and enforce compounding standards across the
country. However, these steps must be proactive and not reactive to avoid
another tragedy similar to NECC. At the forefront, SBOPs must be the
strongest advocates to bring about protection under broad compounding
regulation in their state. Following one or several of the recommendations
below may aid SBOPs in their continued responsibility to ensure public safety
from bad actors providing compounded medications.
A.

Pharmacies/Facilities Should Be Required to Identify Themselves as
Engaging in Compounding.

Compounding facilities should be required to register what compounding
activities they are engaging in and what types of compounds they are
producing. Missouri is one of only a few states that requires pharmacies to
register through the utilization of a multi-class licensure system that allows the
SBOP to track pharmacies on a yearly basis. 233 Missouri’s “Class D” and
“Class H” pharmacy licenses are specific to producing non-sterile and sterile
drugs from bulk substances respectively. 234 Of the licensed pharmacies located
in Missouri this year, 428 pharmacies have valid registrations for either a
“Class D” or “Class H” license. 235 Other states, like Mississippi, require
registrations to know the number of compounding pharmacies, but do not track
those performing sterile compounding. 236 However, some states required no
indication on an individual pharmacy’s registration as to whether or not they
perform compounding, much less sterile compounding, at the time of the
DQSA. 237 Coupling the lack of state identification systems with the facilities
identified by the DQSA’s voluntary registration 238 indicates that there is a need
to identify compounders in the U.S.

232. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal
Food, Drug, and Cosmetic Act, 79 Fed. Reg. 37,742, 37,742 (July 2, 2014).
233. CONGRESSMAN MARKEY ET AL., supra note 126, at 3, 15.
234. MO. CODE REGS. tit. 20 § 2220-2.020 (2013).
235. MO. DIV. OF PROF’L REGISTRATION, Downloadable Listing: Pharmacy, http://pr.mo.
gov/listings-pha.asp (last visited Jan. 21, 2016) (obtained from a spreadsheet of Missouri Board
of Pharmacy License Data filtered licenses to include class D or H).
236. CONGRESSMAN MARKEY ET AL., supra note 126, at 15.
237. Id.
238. Registered Outsourcing Facilities, supra note 192.
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To identify compounders, SBOPs could easily create an additional
question regarding compounding on pharmacy or pharmacist licensing
applications asking if they engage in compounding, and, if so, what type they
are engaged in. The state could decide whether or not to impose fees for
compounders or pharmacies, much like Missouri’s classification does, 239 or
simply use it as an identifier for their records and inspectors since outsourcing
facilities require supervision by a licensed pharmacist. 240 As an example of this
type of implementation, only months after NECC, Massachusetts requested all
pharmacies to report under penalty of law whether or not they were engaging
in sterile compounding. 241 Thirty-nine of over one thousand pharmacies
identified themselves shortly thereafter. 242 The same could go for pharmacists
or pharmacies renewing their licenses yearly or on the scheduled expiration
date.
Some states have elected to change their registration process since the
tragedy, 243 but some states have not. 244 If states choose not to require
registration, it would be possible for the FDA to require all pharmacies to
register as compounders in a national database, similar to the National Provider
Identification database. This database could then be utilized by states during
inspection efforts to ensure proper awareness of those engaging in
compounding activities. Moreover, to help ensure accurate reporting of
compounding activities, SBOPs or the FDA could seek to require management
of facilities to certify where they fall under the FDCA (Section 503A or 503B),
or to indicate they are not engaged in compounding at all during registration
and renewal.
Fixing the problem of compounder identification would be the first and
perhaps most critical step towards building effective regulation and greater
patient safety, and it would come at little cost to agencies. Identification can
provide state and federal inspectors the valuable awareness that may save lives
and allow faster response to compounding complaints. In the near future, states

239. MO. CODE REGS. tit. 20 § 2220-4.010 (2013). Missouri charges a licensing fee to
compounding pharmacists only. Id.
240. Drug Quality and Security Act, supra note 26, at § 105.
241. CONGRESSMAN MARKEY ET AL., supra note 126, at 11.
242. Id.
243. See, e.g., Pharmacy Terminal Distributor of Dangerous Drugs, ST. OHIO BOARD
PHARMACY, http://www.pharmacy.ohio.gov/Documents/Licensing/TDDD/General/Terminal%20
Distributor%20Licensing%20of%20Prescriber%20Practices.pdf (last updated Oct. 8, 2015).
244. See, e.g., Pharmacy Application, PENN. ST. BOARD PHARMACY, http://www.dos.pa.gov/
ProfessionalLicensing/BoardsCommissions/Pharmacy/Documents/Applications%20and%20Form
s/Non-Application%20Documents/PhamrF%20-%20Central%20Processing%20Center.pdf (last
visited Feb. 18, 2016). Pennsylvania has not required identification of compounders via a separate
licensing or registration system. Id.
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should lead the push towards requiring identification or licensure for any
pharmacy, facility, or maybe even pharmacists engaged in compounding.
B.

Increasing Resources for State Boards of Pharmacies (Inspections and
Education of Inspectors)
1. Inspectors and Inspections

Another flaw in the DQSA is that it does not address the patchwork of
state board inspection and enforcement abilities across the U.S. It fails to
realize that SBOPs need additional funding and enhanced or uniform training
for inspectors if they are to effectively carry out their responsibilities and be
relied on by the FDA. Therefore, to truly succeed, the FDA should find ways
to facilitate and standardize compounding inspections, inspector education, and
enforcement through SBOPs. NABP, an independent agency, is currently
working on uniform standards that states may utilize when inspecting
compounders. 245 But without adoption by all states, SBOPs may continue to
enforce standards differently or to overlook pharmacies that may actually
require a higher level of scrutiny during inspection.
To demonstrate the need for standardization and further support, two
SBOPs, Missouri and Ohio, are contrasted from information detailed in the
“State of Disarray” report given to the U.S. House of Representatives in
November of 2012, before the passage of the DQSA. 246 In the report, Missouri
reported 1,570 licensed in-state pharmacies (442 compounding) from the
Missouri SBOP’s (MoSBOP) most recent year on file. 247 However, the
MoSBOP only employs eight inspectors, which, disturbingly enough, is above
the national average. 248 These eight inspectors completed 1,242 inspections at
pharmacies and other facilities related to pharmacy practice in the state, or
roughly 155 pharmacies per inspector. 249 However, this number indicates that
inspectors did not reach about 300 pharmacies, and because a lot can change
year-to-year with pharmacies, especially in the lucrative compounding market,
it is important to have regular inspections. At this time, Missouri is one of few

245. See MODEL STATE PHARMACY ACT, supra note 125.
246. CONGRESSMAN MARKEY ET AL., supra note 126, at 14. The report was compiled from
responses to a series of questions sent to SBOPs “designed to examine the degree to which
individual states [were] capable of overseeing the safety of compounding pharmacy practices”
and enforcement within their state. Id.
247. Id. at 16.
248. Id. at 19. Boards of Pharmacy in the U.S. have anywhere from one to thirty inspectors
with the average being only five inspectors per state. Id. at 26. California has the most with thirty
full time inspectors, however they have over 6,700 pharmacies licensed instate. Id. at 26-27. This
number of licensed pharmacies furthermore, does not include other facilities they inspect
regularly like wholesalers, and manufacturers in their state. Id. at 25.
249. Id. at 34.
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states that maintains the special classification for compounding pharmacies,
inspects them regularly, and actively follows up on non-compliance. 250
In the same report, Ohio reported an estimated 2,700 pharmacies registered
with no indication of how many engaged in compounding. 251 Ohio’s SBOP
employed twenty-two full time inspectors who performed only an estimated
1,100 inspections, or an average of fifty per inspector. 252 Therefore, it is
estimated that around 1,600 pharmacies in Ohio were not inspected in the year
prior to the survey. 253 This comparison illustrates the differences that exist
among SBOP’s inspectors and inspection capabilities. While Missouri’s
inspectors covered a lot of ground—they performed roughly triple the amount
of inspections as Ohio—this naturally raises questions as to the level of
consistency in state-by-state enforcement.
Any remedy to lax inspection levels, though, would ultimately add
additional costs to SBOPs. Hiring new inspectors and paying for advanced
training is not always in the budget for each state and could be created through
federal match programs or solely by the FDA as an arm for enforcing Section
503A themselves. After all, insufficient follow-up was one of the main reasons
the NECC tragedy occurred and why NECC continued to operate for years
after being issued warning letters by the FDA and the MSBP. 254 Working to
create more resources and inspectors will only aid the ongoing inspection and
follow-up processes.
2. Randomized Testing
Another potential solution to increase compound quality and identify bad
actors is to test randomized samples of products from compounding
pharmacies. This may serve as another tool to identify those compounders not
working to sufficiently minimize some of the five risks associated with
compounding. To aid this task, the FDA could implement a mechanism, by
means of funding or through use of their own labs, to allow state submissions
of randomly collected compounding samples for analysis.
Missouri already performs testing on compounds made within the state;
however, the testing is reactive in nature. 255 In fiscal year 2013, Missouri
inspectors responded to twenty-three compounding complaints and performed
potency tests on fifty-six compounded medications seized during inspections

250. MO. BD. OF PHARMACY, ANNUAL REPORT FY 2013 20 (2013) [hereinafter MO.
REPORT].
251. CONGRESSMAN MARKEY ET AL., supra note 126, at 35.
252. Id.
253. Id.
254. Id. at 9.
255. MO. REPORT, supra note 250, at 20.
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or requested as a result of complaints. 256 Results found seven unsatisfactory
compounds ranging in potency from 3.3% to 226.6%. 257 All unsatisfactory
compounds were non-sterile, and five of those seven contained medications
with a narrow therapeutic index. 258 The state then shared its analysis with each
pharmacy and required pharmacies with an unsatisfactory compound to
complete a “quality assurance review” of compounding practices and to
provide a follow-up “corrective action plan” to the board of pharmacy. 259
Although the tests were reactive initially, the state was able to identify and
document compounders with deficiencies and correct them. 260 There is no
doubt the actions of the MoSBOP increased the quality of compounds
produced and ensured the safety of the patients in their state.
Although randomized testing may prove expensive, the insight provided to
SBOPs of possible deficiencies within a compounding facility that may be
otherwise unreported or unchecked is highly useful. It is also a way for
inspectors to test and validate the skills and procedures utilized by
compounders before it may be too late.
3. Independent Accreditation
Another way to reduce strain on state inspectors could be to allow
independent accreditations to serve as compound specific “inspections” in
limited circumstances. 261 Accreditation for compounding is very labor
intensive and can cost a significant amount, but does come with rewards. 262
Compounding accreditations are popularly used as a way for compounders to
“market” and separate themselves from others in the practice. 263 Organizations
like the Pharmaceutical Compounding Accreditation Board (PCAB) 264 offer a
voluntary accreditation process for compounding pharmacies. 265 The process
requires multiple and extremely thorough inspections before accreditation is
obtained. 266 These outside agencies examine a facility’s standard operating
256. Id.
257. Id.
258. Id. Active ingredients in the unsatisfactory compounds included: chloramphenicol,
estriol, estradiol, progesterone, DHEA, testosterone, liothyronine, levothroxine, and omeprazole.
Id.
259. MO. REPORT, supra note 250, at 20.
260. Id.
261. See PCAB ACCREDITATION MANUAL, supra note 61.
262. Id. at 42.
263. Id. at 36.
264. Id. at 1. PCAB’s board of directors include the American College of Apothecaries,
National Community Pharmacists Association, American Pharmacists Association, National
Alliance of State Pharmacy Associations, International Academy of Compounding Pharmacists,
National Home Infusion Association, and the United States Pharmacopeia. Id.
265. Id. at 1.
266. PCAB ACCREDITATION MANUAL, supra note 61, at 31.
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procedures (SOPs) and scrutinize their compliance to USP guidelines much
more than a typical state board inspector may necessarily do in a couple hours
of inspection. 267 While accreditation may not make the pharmacy community
immune from a repeat of NECC, 268 it could help to safeguard the public and
identify the highest quality compounders. States may choose to never require
accreditation by an outside agency, however, accreditation could be considered
as a factor for future enforcement actions and regulation.
VIII. CONCLUSION
Prescription compounding is a dangerous and continually growing market.
Large margins, high utilization, and a growing need for compounds due to
drug shortages and the desire for customized medications have brought out the
deficiencies in regulation. While it is still too early to tell whether the DQSA
will be effective in regulating compounders and ensuring patient safety, its
deficiencies leave unanswered questions as to the effectiveness of regulatory
efforts. The DQSA’s lack of a mandatory registration or identification system
should drive SBOPs to investigate and implement regulations to identify
compounding facilities within their state and to take a tougher stance in
enforcement actions. However, limited SBOP resources and variances between
states’ regulations may stifle truly effective regulation and continue to leave
patients at risk. As we move forward and public awareness of compounding
regulation fades, “pirate” compounders may again look to maximize their
business through manufacturer-like and other risky behaviors. Therefore, it
will be vital for the FDA and SBOPs to continue promulgating regulations that
effectively enforce adherence to good compounding practices set forth by the
USP. Until we ensure regulations are consistently implemented, followed, and
reviewed, bad actors and uneducated compounders will continue to risk the
safety of patients across the country.
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267. Id. at 13.
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